0.05Open0.05Pre Close0 Volume1 Open Interest3.50Strike Price0.00Turnover5708.80%IV46.84%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0407Delta0.0336Gamma129.80Leverage Ratio-6.0981Theta0.0000Rho-5.28Eff Leverage0.0000Vega
Altimmune Stock Discussion
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat con...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet